The role of the renin-angiotensin-aldosterone system in the management of heart failure

Pharmacotherapy

Volumn 20, Issue 11 II, 2000, Pages

  Rodgers, J E ^a   Patterson, J H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; LISINOPRIL; LOSARTAN; OMAPATRILAT; RAMIPRIL; SPIRONOLACTONE; ALDOSTERONE; ANGIOTENSIN; LOOP DIURETIC AGENT; RENIN; VALSARTAN; VASOPEPTIDASE INHIBITOR;

CLINICAL TRIAL; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EXERCISE TOLERANCE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HOSPITALIZATION; HUMAN; MEDICAL SOCIETY; MORBIDITY; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; ARTICLE; ASYMPTOMATIC DISEASE; CARDIOVASCULAR MORTALITY; DIZZINESS; DOSE RESPONSE; EVIDENCE BASED MEDICINE; GYNECOMASTIA; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HYPERTENSION; HYPOTENSION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYMPTOM;

EID: 0033773296     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.20.18.368s.34606     Document Type: Conference Paper

References (55)

1. Effects of enalapril on mortality in severe congestive heart failure: Results of the cooperative north Scandinavian enalapril survival study
2. Effect of enalapril on mortality of the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
3. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
4. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial (SAVE)
5. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacologic approaches
6. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996)
7. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
8. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
9. Assessment of treatment with lisinopril and survival (ATLAS)
10. ACE inhibitor-versus angiotensin II blocker-induced cough and angioedema
11. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology
12. Use of baclofen to suppress cough induced by angiotensin-converting enzyme inhibitors
13. Angiotensin-converting enzyme inhibition does not suppress plasma angiotensin II increase during exercise in humans
14. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor
15. Heterogenity of angiotensin synthetic pathways and receptor subtypes: Physiological and pharmacological implications
16. Chymase-dependent angiotensin II forming systems in the heart
17. Stimulation of different subtypes of angiotensin II receptors, ATI and ATII receptors, regulates STAT activation by negative crosstalk
18. Analysis of functional domains of angiotensin II type 2 receptor involved in apoptosis
19. Hemodynamics and neurohormonal effects of the angiotensin II antagonist losartan in patients with congestive heart failure
20. Losartan in heart failure: Hemodynamic effects and tolerability
21. Candesartan cilexetil improves exercise tolerance and symptoms in patients with congestive heart failure
22. A randomized trial evaluating tolerability of candesartan cilexetil for patients with congestive heart failure and intolerance to angiotensin converting enzyme inhibitors
23. Effects of losartan on exercise capacity, morbidity, and mortality in patients with symptomatic heart failure
24. Comparison of candesartan, enalapril and their combination in congestive heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
25. Irbesartan combined with conventional therapy, including angiotensin converting enzyme inhibitors, in heart failure
26. Clinical benefits of long-term angiotensin II receptor blockade in patients with severe symptoms of congestive heart failure despite full angiotensin-converting enzyme inhibition
27. Angiotensin II-mediated cardiac hypertrophy in adult rats
28. Effects of the AT1 receptor antagonist losartan on angiotensin II induced hypertrophy of rat cardiomyocytes
29. Effect of angiotensin II blockade on cardiac hypertrophy and remodeling: A review
30. Effects of losartan and captopril on left ventricular volumes in elderly patients with heart failure: Results of the ELITE ventricular function substudy
31. Randomised trial of losartan versus captopril in patients over 65 with heart failure (evaluation of losartan in the elderly study, ELITE)
32. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomized trial - The losartan heart failure survival study - ELITE II
33. Angiotensin II receptor blockade combined to ACE inhibition improves left ventricular dilation and exercise ejection fraction in congestive heart failure
34. Comparison of candesartan, enalapril and their combination in congestire heart failure: Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study
35. Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors
36. Candesartan in heart failure - Assessment of reduction in mortality and morbidity (CHARM): Rationale and design
37. Rationale and design of the valsartan heart failure trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure
38. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL trial design. Optimal therapy in myocardial infarction with the angiotensin II antagonist losartan
39. Enhancing cardiac protection after myocardial infarction: Rationale for newer clinical trials of angiotensin receptor blockers
40. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog
41. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
42. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
43. Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid depletion
44. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone evaluation study investigators
45. Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure
46. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans
47. Effects of omapatrilat in low, normal, and high renin experimental hypertension
48. Bradykinin metabolism in the postinfarcted rat heart: Role of ACE and neutral endopeptidase
49. The safety and 24-hour antihypertensive efficacy of the vasopeptidase inhibitor omapatrilat: A pilot study
50. Efficacy and safety of omapatrilat, a new vasopeptidase inhibitor
51. Chronic dual inhibition of angiotensin-converting enzyme and neutral endopeptidase during the development of left ventricular dysfunction in dogs
52. Long-term beneficial hemodynamic and neurohormonal effects of vasopeptidase inhibition with omapatrilat in heart failure
53. Cardiac, renal and endocrine effects of three month treatment of chronic heart failure with the vasopeptidase inhibitor, omapatrilat
54. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomized trial
55. Beneficial effects of vasopeptidase inhibition on mortality and morbidity in heart failure: Evidence from the omapatrilat heart failure program